Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Report: Allergan CEO in line for $100M payout from Actavis deal
Allergan Chairman and CEO David Pyott stands to earn $100 million once its multi-billion-dollar merger with Actavis is consummated later this year.
The Orange County Business Journal, citing a federal regulatory filing, detailed the big payout coming for Pyott. He’ll get $89 million in cash and stock of the combined company, as well as other payments, but he must also give up unvested equity awards, according to the story. Read more
2. Overactive bladder treatment: Advanced Uro-solutions bought by Medtronic
Medtronic has wrapped up yet another acquisition, buying Advanced Uro-Solutions, a Tennessee company whose neurostimulation products focus on treating patients with overactive bladder, for an undisclosed amount of money.
The deal is relatively small, but crucial, because it adds another variation of neurostimulation technology to the device giant’s portfolio. Read more
1. Report: Is Boston Scientific closing in on deal for Endo’s AMS medical device unit?
Endo International, PLC may have found a buyer for its American Medical Systems subsidiary after months of speculation that the Irish pharma company had put its medical device business on the block.
Boston Scientific is said to be nearing a deal to buy Minnetonka, Minn.-based AMS, according to a report from Reuters news service, which cited sources “familiar with the matter.” Read more
